ArticleJournal of medicinal chemistry2025
Evaluating Naphthalene-Modified Metallosalen Complexes as Anticancer Agents.
Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In Vitro Evaluation of Novel Synthetic Benzimidazolium-Chalcone Hybrids: Antioxidant and Regenerative Effects in Diabetic Wound Healing.Applied biochemistry and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The development of novel naphthalene-modified metallosalens incorporating Pt(II) and Pd(II) presents a promising approach to addressing limitations in cancer therapies. These metallosalens were synthesized and characterized using single crystal X-ray diffraction (sc-XRD), UV-vis spectroscopy, nuclear magnetic resonance (NMR) spectroscopy, and C, H, N elemental analysis. Their strong metal coordination and enhanced electronic interactions, stemming from π-conjugated aromatic structures, improved their DNA-binding affinity and cytotoxic efficacy. Biological assays confirmed significant cytotoxicity in A375 (melanoma) and H292 (nonsmall cell lung cancer) cell lines, while demonstrating minimal toxicity toward HSAEC healthy lung cells. PtL1 and PtL2 exhibited superior activity, inducing apoptosis with high selectivity for cancer cells, as validated by Incucyte Caspase-3/7 Green Dye assays. These findings highlight the potential of naphthalene-modified metallosalens as broad-spectrum cancer therapies, balancing efficacy with reduced off-target effects, and underscore the importance of ligand design and metal coordination in advancing next-generation chemotherapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.